Bridgeway Capital Management’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Bridgeway Capital Management’s Portfolio TLOG Stock Details TLOG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-18,553	Closed	-$32K	–	1510
2015 Q4	$32K	Hold	18,553	–	–	﹤0.01%	1414
2015 Q3	$35K	Buy	18,553 +8,503	+85%	+$20.2K	﹤0.01%	1444
2015 Q2	$24K	Hold	10,050	–	–	﹤0.01%	1483
2015 Q1	$44K	Hold	10,050	–	–	﹤0.01%	1459
2014 Q4	$48K	Buy	+10,050	New	+$45K	﹤0.01%	1434

Other funds holding TLOG

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geneva Advisors Chicago, Illinois $5.81B AUM 23.71% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Bridgeway Capital Management's TLOG Position: Q1 2016 in Review

Bridgeway Capital Management sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q1 2016, closing a stake of 18,553 shares — an estimated $32K sold.

Bridgeway Capital Management first reported a position in TLOG in Q4 2014 and held it in 5 quarters. The position peaked at $48K in Q4 2014. 25 funds tracked by Wall St. Rank hold TLOG as of Q1 2016.

Bridgeway Capital Management reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q1 2016 after selling out during the quarter.
Bridgeway Capital Management sold 18,553 TetraLogic Pharmaceuticals Corporation shares in Q1 2016, an estimated $32K.
Bridgeway Capital Management first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2014 and held it in 5 quarters.
Bridgeway Capital Management's TetraLogic Pharmaceuticals Corporation position peaked at $48K in Q4 2014.
25 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q1 2016.

Based on Bridgeway Capital Management's 13F filing for Q1 2016, filed 16 May 2016.